PPD Receives Patient First Award at Medidata NEXT

PPD, Inc. (PPD) has been selected by Medidata^®, part of Dassault Systèmes, to receive its Patient First Award. The award recognizes a company that is trailblazing ways to improve lives by demonstrating a commitment to decreasing patient burden in clinical trials through technology.

The nomination was based on PPD's use of electronic clinical outcome assessments (eCOA), augmented by Medidata's platform, to collect direct patient data and provide patients an uninterrupted experience from Phase III to open-label extension studies. The unified collection approach allows for immediate access of patient data in a single system in order to stage dosing and monitor the patient's condition.

The eCOA data is also leveraged to automatically determine patient eligibility by combining critical patient information with the clinical record. Patients from the Phase III study who meet the Evidence of Clinically Meaningful Deterioration (ECMD) criteria are then immediately enrolled in open-label extension. Both studies look and feel the same and do not require additional effort to record patient data in order to provide a consistent patient experience. This distinct approach combines modern technologies with integrated process improvement and real-time analytics to provide comprehensive, digitally enabled solutions for patient and sponsor challenges.

"PPD is pleased to be recognized for our company's commitment to reducing patient burden and trial complexity," said Susan Atkinson, Ph.D., senior vice president of global biometrics for PPD, who accepted the award on the company's behalf at the fourth annual Medidata Customer Awards. "Our use of eCOA has enabled us to recognize efficiencies to provide patients a more streamlined experience, as well as automate and accelerate drug development for our customers."

Michael Pray, executive vice president of global sales at Medidata, said, "The Medidata Customer Award highlights the most innovative approaches to the digital transformation of life sciences. We are proud to recognize PPD for their clinical advancements and dedication to patients around the world."

The award was presented at the Medidata NEXT conference, held Nov. 12 and 13 in New York City.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.